مارلين هويستيس
Huestis, Marilyn
VIAF ID: 36356442 (Personal)
Permalink: http://viaf.org/viaf/36356442
Preferred Forms
- 100 1 _ ‡a Huestis, Marilyn
- 100 0 _ ‡a مارلين هويستيس
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ | |
Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients | |
Oral fluid nicotine markers to assess smoking status and recency of use | |
Oral fluid testing for drugs of abuse | |
Patterns of methamphetamine use during pregnancy: results from the Infant Development, Environment, and Lifestyle (IDEAL) Study | |
Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA | |
Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids | |
Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study | |
Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration | |
Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. | |
Physiological regulation in cigarette exposed infants: an examination of potential moderators | |
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence | |
Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users | |
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults | |
Population-based input function modeling for [(18)F]FMPEP-d 2, an inverse agonist radioligand for cannabinoid CB1 receptors: validation in clinical studies | |
Postmortem diagnosis and toxicological validation of illicit substance use. | |
The potential role of oral fluid in antidoping testing | |
Prenatal methamphetamine use and neonatal neurobehavioral outcome | |
Prenatal tobacco exposure and infant stress reactivity: role of child sex and maternal behavior | |
Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes | |
Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder | |
Psychomotor function in chronic daily Cannabis smokers during sustained abstinence | |
Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry | |
Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens | |
Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent | |
Relative performance of common biochemical indicators in detecting cigarette smoking | |
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial | |
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans | |
Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series | |
Selection and optimization of hydrolysis conditions for the quantification of urinary metabolites of MDMA. | |
Sensitive gas chromatography-mass spectrometry method for simultaneous measurement of MDEA, MDMA, and metabolites HMA, MDA, and HMMA in human urine. | |
Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GC-MS following controlled codeine administration | |
Signal-averaged electrocardiogram in physically healthy, chronic 3,4-methylenedioxymethamphetamine (MDMA) users | |
Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry | |
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis | |
Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylene | |
Simultaneous quantification of opiates, cocaine, and metabolites in hair by LC-APCI-MS/MS. | |
Simultaneous quantification of Δ(9)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry | |
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users | |
Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal | |
Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans | |
Strategies for quitting among non-treatment-seeking marijuana smokers. | |
Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes | |
Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. | |
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications | |
Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases | |
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia | |
Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age. | |
Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. | |
Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers | |
Toxicology and Analysis of Psychoactive Tryptamines | |
Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes | |
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans |